In Reply We disagree with Dr Haring’s statements that The Testosterone Trials (T-Trials)^1- 3 had low generalizability and showed some benefits in one area and some risks in others.

The goal of the T-Trials^1- 3 was to determine if testosterone treatment of symptomatic older men with low testosterone would be efficacious in any way. Toward this goal, we selected only men 65 years or older who had unequivocally low testosterone values. The median baseline testosterone level of 234 ng/dL confirms that the participants indeed had low testosterone levels. In addition, men had to have symptoms that could be ascribed to low testosterone. We included men with the comorbidities common at this age, although we did exclude men at high risk of conditions, such as prostate cancer, that testosterone might exacerbate. The results of the T-Trials^1- 3 are therefore highly generalizable to men 65 years and older who have low testosterone levels and symptoms that might motivate them to seek treatment.

在回复我们不同意哈林博士的陈述，睾酮试验（T-试验）^{1 - 3}具有较低的普遍性，并显示在一个区域一些好处，而在另一些风险。

T型试验的目标，^{1 - 3}是确定的症状的老年男性睾丸激素水平低睾酮治疗会以任何方式有效。为了实现这一目标，我们只选择了65岁或以上的男性睾丸激素值绝对较低的男性。中位基线睾丸激素水平为234 ng / dL，证实参与者的睾丸激素水平确实很低。此外，男人必须有可能归因于睾丸激素水平低的症状。尽管我们确实排除了患有睾丸激素可能会加重的高患病风险（例如前列腺癌）的男性，但我们包括了这个年龄段常见的合并症的男性。T形试验的结果^{1 3 -} 因此，对于那些睾丸激素水平低和症状可能促使他们寻求治疗的65岁及65岁以上的男性，这些药物具有高度的普遍性。